Cargando…

Population-Based Outcomes in NSCLC

Detalles Bibliográficos
Autor principal:	Edelman, Martin J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050018/ https://www.ncbi.nlm.nih.gov/pubmed/32328552 http://dx.doi.org/10.1093/jncics/pkz022

Ejemplares similares

NSCLC metastasis: going with ELMO3
por: Goyette, Marie-Anne, et al.
Publicado: (2014)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis
por: Vansteenkiste, Johan
Publicado: (2017)

New data: new options for front-line therapy in NSCLC?
por: Reinmuth, Niels
Publicado: (2018)

Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC
por: Ewer, Michael S., et al.
Publicado: (2021)

Surgical Insights Are Essential to Integration of Immune Therapy in Resectable NSCLC
por: Donington, Jessica S.
Publicado: (2021)

What Can We Save for the First-Line Treatment of NSCLC in 2016?
por: Rossi, David
Publicado: (2017)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Uncommon EGFR-Mutant NSCLC—One Drug Does Not Fit All
por: Wang, Yang, et al.
Publicado: (2023)

Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks
por: Stravopodis, Dimitrios J., et al.
Publicado: (2023)

Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC
por: Wang, Hangjun, et al.
Publicado: (2018)

Defining Factors That Allow for a More Personalized Approach to Stage I NSCLC
por: Donington, Jessica S.
Publicado: (2022)

Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?
por: Bahl, A, et al.
Publicado: (2001)

It’s Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?
por: Caiola, Elisa, et al.
Publicado: (2020)

Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
por: Gravara, Luigi Della, et al.
Publicado: (2020)

Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation
por: Shukla, Nikhil A, et al.
Publicado: (2020)

Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC
por: Hamann, Heidi A., et al.
Publicado: (2022)

Notching up a new therapeutic strategy for Non-Small Cell Lung Carcinoma (NSCLC)
por: Maraver, Antonio, et al.
Publicado: (2012)

Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC—is it justified?
por: Weder, Walter, et al.
Publicado: (2021)

The Biology and Therapeutic Potential of the Src-YAP Axis in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2022)

The Cradle to Prison Pipeline: An American Health Crisis
por: Wright Edelman, Marian
Publicado: (2007)

Smoking and TAVR
por: Edelman, J. James, et al.
Publicado: (2019)

Introduction to the Special Series: National Drug Abuse Treatment Clinical Trials Network and the Opioid Use Disorder Care Continuum—20 years of research informing practice
por: Saxon, Andrew J., et al.
Publicado: (2022)

Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
por: Monteverdi, Sara, et al.
Publicado: (2020)

Metastasis Patterns and Prognosis of Octogenarians with NSCLC: A Population-based Study
por: Gu, Yu, et al.
Publicado: (2020)

First-line immune-chemotherapy combination for squamous NSCLC is already a reality
por: Hendriks, Lizza E. L., et al.
Publicado: (2020)

Improved understanding of NSCLC immunotherapy response mechanisms from single-cell analysis
por: Bienkowska, Kamila Justyna, et al.
Publicado: (2023)

Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Substance use and the HIV care continuum: important advances
por: Korthuis, P. Todd, et al.
Publicado: (2018)

MLTI-03. The relevance of the count of brain metastases for treatment and outcome in NSCLC
por: Reinecke, David, et al.
Publicado: (2021)

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
por: Aldea, Mihaela, et al.
Publicado: (2020)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

PET-Plan: potential for dose escalation by target volume reduction in locally advanced NSCLC
por: de Jong, Evelyn E. C., et al.
Publicado: (2020)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

Multimodal Imaging and Hybrid Scanners
por: Azhari, Haim, et al.
Publicado: (2007)

Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic
por: Kumar, Sameera, et al.
Publicado: (2020)

EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
por: Steuer, Conor E., et al.
Publicado: (2020)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_svekh7qgs7lch16emng0uk8cna